{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:26:10Z","timestamp":1789619170218,"version":"build-2803163510"},"reference-count":91,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Purpose of review: Tamoxifen and aromatase inhibitors can be considered as some of the first targeted therapies. For the past 30 years, they were the endocrine treatment standard in the advanced and early breast cancer setting. CDK4\/6 inhibitors, however, are the first substances in almost two decades to broadly improve the therapeutic landscape of hormone receptor-positive breast cancer patients for the upcoming years. This review is designed to discuss the recent history, current role, future directions and opportunities of this substance class. Recent findings: The CDK4\/6 inhibitors abemaciclib, dalpiciclib, palbociclib and ribociclib have all demonstrated a statistically significant improvement in progression-free survival in advanced disease. However, to date, abemaciclib and ribociclib are the only CDK4\/6 inhibitors to have shown an improvement in overall survival in patients with metastatic breast cancer. Moreover, abemaciclib is the first CDK4\/6 inhibitor to also reduce the risk of recurrence in those with early-stage disease. Further CDK inhibitors, treatment combinations with other drugs and different therapy sequences are in development. Summary: Achieving significant improvements in survival rates in the advanced and early breast cancer treatment setting, CDK4\/6 inhibitors have set a new standard of care for patients with advanced breast cancer. It remains important to better understand resistance mechanisms to be able to develop novel substances and treatment sequences.<\/jats:p>","DOI":"10.3390\/cancers15061763","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T04:39:45Z","timestamp":1678855185000},"page":"1763","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["CDK4\/6 Inhibitors\u2014Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-0649","authenticated-orcid":false,"given":"Naiba","family":"Nabieva","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"},{"name":"GynPraxis Dr. Ernst and Colleagues, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4885-8471","authenticated-orcid":false,"given":"Peter","family":"Fasching","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander Universit\u00e4t Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0140-6736(01)72384-7","article-title":"On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases","volume":"148","author":"Beatson","year":"1896","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1971.33","article-title":"A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474","volume":"25","author":"Cole","year":"1971","journal-title":"Br. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group","volume":"19","author":"Mouridsen","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial","volume":"20","author":"Osborne","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials","volume":"386","author":"Dowsett","year":"2015","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.18.01967","article-title":"Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results from TEXT and SOFT","volume":"38","author":"Pagani","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1200\/JCO.21.02179","article-title":"Everolimus Added to Adjuvant Endocrine Therapy in Patients with High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer","volume":"40","author":"Bachelot","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000524879","article-title":"AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022","volume":"17","author":"Ditsch","year":"2022","journal-title":"Breast Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1634\/theoncologist.2017-0423","article-title":"Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance","volume":"23","author":"Brufsky","year":"2018","journal-title":"Oncologist"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2018.04.009","article-title":"Mechanisms of resistance in estrogen receptor positive breast cancer: Overcoming resistance to tamoxifen\/aromatase inhibitors","volume":"41","author":"Mills","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13058-022-01510-6","article-title":"Cellular mechanisms underlying response and resistance to CDK4\/6 inhibitors in the treatment of hormone receptor-positive breast cancer","volume":"24","author":"Watt","year":"2022","journal-title":"Breast Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: A randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+\/HER2\u2212 Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S1384","DOI":"10.1016\/j.annonc.2022.08.010","article-title":"LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+\/HER2- advanced breast cancer (DAWNA-2): A phase III trial","volume":"33","author":"Xu","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","article-title":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: A randomized, phase 3 trial","volume":"27","author":"Xu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Nabieva, N., and Fasching, P.A. (2021). Endocrine Treatment for Breast Cancer Patients Revisited\u2014History, Standard of Care, and Possibilities of Improvement. Cancers, 13.","DOI":"10.3390\/cancers13225643"},{"key":"ref_28","unstructured":"Sledge, G., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Okera, M., Masuda, N., Kaufman, P.A., and Koh, H. (2022, January 6\u201310). Final Overall Survival Analysis of MONARCH-2: A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Proceedings of the 2022 San Antonio Breast Cancer Symposium, San Antonio, TX, USA."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S1384","DOI":"10.1016\/j.annonc.2022.08.009","article-title":"LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)","volume":"33","author":"Goetz","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"LBA1003","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1003","article-title":"Overall survival (OS) with first-line palbociclib plus letrozole (PAL + LET) versus placebo plus letrozole (PBO + LET) in women with estrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer (ER+\/HER2\u2212 ABC): Analyses from PALOMA-2","volume":"40","author":"Finn","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","article-title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: Updated overall survival","volume":"32","author":"Slamon","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"PD2-04","DOI":"10.1158\/1538-7445.SABCS20-PD2-04","article-title":"Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive\/human epidermal growth factor receptor 2 negative (HR+\/HER2\u2212) advanced breast cancer (ABC) treated with endocrine therapy (ET) \u00b1 ribociclib","volume":"81","author":"Tripathy","year":"2021","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"693104","DOI":"10.3389\/fonc.2021.693104","article-title":"Clinical and Pharmacologic Differences of CDK4\/6 Inhibitors in Breast Cancer","volume":"11","author":"George","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.breast.2020.08.011","article-title":"Initial experience with CDK4\/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer\u2014Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany","volume":"54","author":"Schneeweiss","year":"2020","journal-title":"Breast"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1055\/a-1880-0087","article-title":"Implementation of CDK4\/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients\u2014Data from the Real-World Registry PRAEGNANT","volume":"82","author":"Engler","year":"2022","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(19)30420-6","article-title":"Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: A systematic review and network meta-analysis","volume":"20","author":"Giuliano","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2020.12.013","article-title":"Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: A phase III randomised controlled trial-PEARL","volume":"32","author":"Martin","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2022.03.006","article-title":"Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study","volume":"168","author":"Martin","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Lu, Y.-S., Bin Mohd Mahidin, E.I., Azim, H., Eralp, Y., Yap, Y.-S., Im, S.-A., Rihani, J., Bowles, J., Alfaro, T.D., and Wu, J. (2022, January 6\u201310). Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients with Aggressive HR+\/HER2\u2212 Advanced Breast Cancer Treated with Ribociclib + Endocrine Therapy vs Physician\u2019s Choice Combination Chemotherapy. Proceedings of the 2022 San Antonio Breast Cancer Symposium, San Antonio, TX, USA.","DOI":"10.1158\/1538-7445.SABCS22-GS1-10"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"LBA1004","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1004","article-title":"A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4\/6 inhibition (CDK 4\/6i) in patients (pts) with unresectable or hormone receptor\u2013positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial","volume":"40","author":"Kalinsky","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_44","unstructured":"(2022, December 15). Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): A randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_46","unstructured":"Johnston, S., Toi, M., O\u2019Shaughnessy, J., Rastogi, P., Campone, M., Neven, P., Huang, C.-S., Huober, J., Jaliffe, G.G., and Cicin, I. (2022, January 6\u201310). Abemaciclib plus endocrine therapy for HR+, HER2\u2212, node-positive, high-risk early breast cancer: Results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes. Proceedings of the 2022 San Antonio Breast Cancer Symposium, San Antonio, TX, USA."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42\/AFT-05\/BIG-14-03)","volume":"40","author":"Gnant","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.20.03639","article-title":"Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial","volume":"39","author":"Loibl","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(20)30642-2","article-title":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): Interim analysis of a multicentre, open-label, randomised, phase 3 study","volume":"22","author":"Mayer","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2\u2212, Node-Positive, High-Risk, Early Breast Cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1200\/JCO.21.02742","article-title":"FDA Approval Summary: Abemaciclib with Endocrine Therapy for High-Risk Early Breast Cancer","volume":"40","author":"Royce","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamaoncol.2022.1488","article-title":"Treatment with Adjuvant Abemaciclib Plus Endocrine Therapy in Patients with High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial","volume":"8","author":"Martin","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: A patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","article-title":"NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4\/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1093\/annonc\/mdy448","article-title":"Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer","volume":"29","author":"Cottu","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejca.2022.01.014","article-title":"Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer","volume":"166","author":"Delaloge","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","article-title":"Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR(+)\/HER2(\u2212) Breast Cancer","volume":"26","author":"Hurvitz","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","article-title":"Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): An open-label, multicentre, randomised, phase 2 trial","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/annonc\/mdx630","article-title":"Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: Results of the prospective Evaluate-TM study with 3941 patients","volume":"29","author":"Nabieva","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejca.2018.03.020","article-title":"Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study","volume":"96","author":"Nabieva","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Wallwiener, M., Nabieva, N., Feisst, M., Fehm, T., de Waal, J., Rezai, M., Baier, B., Baake, G., Kolberg, H.C., and Guggenberger, M. (2019). Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: Results of the prospective observational EvAluate-TM study. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5806-y"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1200\/JCO.2015.63.8619","article-title":"Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence","volume":"34","author":"Chirgwin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.breast.2017.08.008","article-title":"Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry","volume":"37","author":"Muller","year":"2018","journal-title":"Breast"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1634\/theoncologist.2019-0551","article-title":"Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer after Endocrine Therapy","volume":"25","author":"Kaufman","year":"2020","journal-title":"Oncologist"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e1346","DOI":"10.1634\/theoncologist.2020-0084","article-title":"Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2\u2212 Advanced Breast Cancer","volume":"25","author":"Goetz","year":"2020","journal-title":"Oncologist"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Harbeck, N., Franke, F., Villanueva-Vazquez, R., Lu, Y.S., Tripathy, D., Chow, L., Babu, G.K., Im, Y.H., Chandiwana, D., and Gaur, A. (2020). Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: Results from a phase III randomized clinical trial (MONALEESA-7). Ther. Adv. Med. Oncol., 12.","DOI":"10.1177\/1758835920943065"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.breast.2020.09.008","article-title":"Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study","volume":"54","author":"Fasching","year":"2020","journal-title":"Breast"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-018-4769-z","article-title":"Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: Results from MONALEESA-2","volume":"170","author":"Verma","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/annonc\/mdy012","article-title":"Impact of palbociclib plus letrozole on patient-reported health-related quality of life: Results from the PALOMA-2 trial","volume":"29","author":"Rugo","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","article-title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: Patient-reported outcomes from the PALOMA-3 trial","volume":"27","author":"Harbeck","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1200\/JCO.2022.40.16_suppl.1017","article-title":"Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+\/HER2- advanced breast cancer (ABC) in MONALEESA(ML)-2","volume":"40","author":"Hart","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41416-021-01415-9","article-title":"Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"125","author":"Burris","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1200\/JCO.21.01918","article-title":"Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS\/AFT-05\/ABCSG-42\/BIG-14-03)","volume":"40","author":"Mayer","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.annonc.2022.03.006","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Safety and patient-reported outcomes from the monarchE study","volume":"33","author":"Rugo","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2147\/PPA.S254934","article-title":"Oncologist and Patient Preferences for Attributes of CDK4\/6 Inhibitor Regimens for the Treatment of Advanced\/Metastatic HR Positive\/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling","volume":"14","author":"Maculaitis","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1016\/j.clbc.2021.08.007","article-title":"The Effects of HER2 on CDK4\/6 Activity in Breast Cancer","volume":"22","author":"Sinclair","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1158\/1078-0432.CCR-20-0844","article-title":"Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial","volume":"26","author":"Ciruelos","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.clbc.2019.05.010","article-title":"Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b\/2 Trial","volume":"19","author":"Goel","year":"2019","journal-title":"Clin. Breast Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(20)30112-1","article-title":"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): A randomised, open-label, phase 2 trial","volume":"21","author":"Tolaney","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41523-021-00311-y","article-title":"Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer","volume":"7","author":"Spring","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.clbc.2021.03.005","article-title":"A Phase I\/Ib Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-Positive Advanced Breast Cancer after Trastuzumab and Taxane Therapy","volume":"21","author":"Haley","year":"2021","journal-title":"Clin. Breast Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000524789","article-title":"AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022","volume":"17","author":"Thill","year":"2022","journal-title":"Breast Care"},{"key":"ref_83","unstructured":"Janni, W., Fehm, T., M\u00fcller, V., Schochter, F., De Gregorio, A., Decker, T., Hartkopf, A., Just, M., Sagasser, J., and Schmidt, M. (2022, January 6\u201310). Omission of chemotherapy in the treatment of HER2-positive and hormone-receptor positive metastatic breast cancer\u2014Interim results from the randomized phase 3 DETECT V trial. Proceedings of the 2022 San Antonio Breast Cancer Symposium, San Antonio, TX, USA."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Canino, F., Piacentini, F., Omarini, C., Toss, A., Barbolini, M., Vici, P., Dominici, M., and Moscetti, L. (2022). Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23137079"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamaoncol.2016.0922","article-title":"Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib","volume":"2","author":"Prat","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1093\/oncolo\/oyac010","article-title":"Ribociclib Improves Overall Survival in HR+\/HER2\u2212 Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes","volume":"27","author":"Jacobson","year":"2022","journal-title":"Oncologist"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.annonc.2021.03.037","article-title":"23P CDK4\/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive\/HER2-negative (HR+\/HER2\u2212) advanced breast cancer (ABC): A retrospective analysis of real-world data","volume":"32","author":"Tolosa","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_88","unstructured":"Mayer, E., Ren, Y., Wagle, N., Mahtani, R., Ma, C., DeMichele, A., Cristofanilli, M., Meisel, J., Miller, K.D., and Jolly, T. (2022, January 6\u201310). PACE: Palbociclib After CDK and Endocrine Therapy A Randomized Phase II Study of Fulvestrant +\/\u2212 Palbociclib after Progression on CDK4\/6 inhibitor for HR+\/HER2\u2212 Metastatic Breast Cancer. Proceedings of the 2022 San Antonio Breast Cancer Symposium, San Antonio, TX, USA."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1200\/JCO.2022.40.16_suppl.1022","article-title":"Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+\/HER2\u2212 breast cancer and an ESR1 mutation after progression on prior therapies","volume":"40","author":"Damodaran","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1158\/1078-0432.CCR-21-2272","article-title":"Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study","volume":"28","author":"Tan","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3892\/or.2022.8316","article-title":"Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway","volume":"47","author":"Tsao","year":"2022","journal-title":"Oncol. Rep."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/6\/1763\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:54:56Z","timestamp":1760122496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/6\/1763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":91,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["cancers15061763"],"URL":"https:\/\/doi.org\/10.3390\/cancers15061763","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]}}}